Structure-Based Optimization of Coumarin hA3 Adenosine Receptor Antagonists

Journal of Medicinal Chemistry
2020.0

Abstract

Adenosine receptors participate in many physiological functions. Molecules that may selectively interact with one of the receptors are favorable multifunctional chemical entities to treat or decelerate the evolution of different diseases. 3-Arylcoumarins have already been studied as neuroprotective agents by our group. Here, differently 8-substituted 3-arylcoumarins are complementarily studied as ligands of adenosine receptors, performing radioligand binding assays. Among the synthesized compounds, selective A<sub>3</sub> receptor antagonists were found. 3-(4-Bromophenyl)-8-hydroxycoumarin (compound <b>4</b>) displayed the highest potency and selectivity as A<sub>3</sub> receptor antagonist (<i>K</i><sub>i</sub> = 258 nM). An analysis of its X-ray diffraction provided detailed information on its structure. Further evaluation of a selected series of compounds indicated that it is the nature and position of the substituents that determine their activity and selectivity. Theoretical modeling calculations corroborate and explain the experimental data, suggesting this novel scaffold can be involved in the generation of candidates as multitarget drugs.

Knowledge Graph

Similar Paper

Structure-Based Optimization of Coumarin hA<sub>3</sub> Adenosine Receptor Antagonists
Journal of Medicinal Chemistry 2020.0
Progress in the development of small molecules as new human A<sub>3</sub> adenosine receptor ligands based on the 3-thiophenylcoumarin core
MedChemComm 2016.0
4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as New Potent and Selective Human A<sub>3</sub>Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand−Receptor Modeling Studies
Journal of Medicinal Chemistry 2006.0
New 2-Arylpyrazolo[3,4-c]quinoline Derivatives as Potent and Selective Human A<sub>3</sub>Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand−Receptor Modeling Studies
Journal of Medicinal Chemistry 2007.0
1,2,4-Triazolo[1,5-a]quinoxaline as a Versatile Tool for the Design of Selective Human A<sub>3</sub>Adenosine Receptor Antagonists:  Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives
Journal of Medicinal Chemistry 2005.0
1,2,4-Triazolo[4,3-a]quinoxalin-1-one Moiety as an Attractive Scaffold To Develop New Potent and Selective Human A<sub>3</sub> Adenosine Receptor Antagonists:  Synthesis, Pharmacological, and Ligand−Receptor Modeling Studies
Journal of Medicinal Chemistry 2004.0
Synthesis, ligand–receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists
Bioorganic &amp; Medicinal Chemistry 2008.0
Discovery and Structure–Activity Relationship Studies of Novel Adenosine A<sub>1</sub> Receptor-Selective Agonists
Journal of Medicinal Chemistry 2022.0
Synthesis, Molecular Modeling, and Selective Inhibitory Activity against Human Monoamine Oxidases of 3-Carboxamido-7-Substituted Coumarins
Journal of Medicinal Chemistry 2009.0
Development of selective agents targeting serotonin 5HT<sub>1A</sub> receptors with subnanomolar activities based on a coumarin core
MedChemComm 2017.0